Jennifer Lavrrar, Jane Hata, Jeanette Block REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JANE HATA, bioMérÃeu
Jennifer Lavrrar, Jane Hata, Jeanette Block
REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007JANE HATA, bioMérÃeux Inc, DurhamReports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter Baumanii. Investigators found varying susceptibility and resistance patterns across the United States that highlight the organisms ability to adapt. Nicola Solomon spoke withJane Hataof bioMérÃeux.
Tags
Related Episodes
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers
“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i
Audio Journal of Oncology Volume 16 Number 11
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology